A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma-Reference-Cited by-同舟云学术

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Published:2021-12 Issue:12 Volume:27 Page:2212-2223
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Kjeldsen Julie Westerlin^ORCID,Lorentzen Cathrine Lund,Martinenaite Evelina,Ellebaek Eva^ORCID,Donia Marco^ORCID,Holmstroem Rikke Boedker^ORCID,Klausen Tobias Wirenfeldt,Madsen Cecilie Oelvang,Ahmed Shamaila Munir,Weis-Banke Stine Emilie^ORCID,Holmström Morten Orebo,Hendel Helle Westergren,Ehrnrooth Eva,Zocca Mai-Britt,Pedersen Ayako Wakatsuki,Andersen Mads Hald,Svane Inge Marie^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-021-01544-x.pdf

Reference59 articles.

1. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239–1251 (2019).

2. Weber, J. S., Postow, M., Lao, C. D. & Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21, 1230–1240 (2016).

3. Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).

4. Ascierto, P. A. et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann. Oncol. 28, v611–v612 (2017).

5. Angeles, L. Warming ‘cold’ melanoma with TLR9 agonists. Cancer Discov. 8, 670 (2018).

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth;Biomedicine & Pharmacotherapy;2024-10

2. Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma;Cancers;2024-09-06

3. Inhibitory effect of human indoleamine 2,3-dioxygenase 1 (hIDO1) by kazinols of 1,3-diphenylpropane derivatives;Applied Biological Chemistry;2024-09-04

4. LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer;Molecular Cancer;2024-09-02

5. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges;Acta Pharmaceutica Sinica B;2024-09